Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibody

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Hartung, Franziska ^a   Stühmer, Walter ^a   Pardo, Luis A ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

10.1; Eag1; KV; ScFv62 TRAIL

Indexed keywords

CISPLATIN; CYCLOHEXIMIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYBRID PROTEIN; KV10.1 SPECIFIC SCFV62 ANTIBODY FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV10.1; ROSCOVITINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TANESPIMYCIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KCNH1 PROTEIN, HUMAN; POTASSIUM CHANNEL HERG; TNFSF10 PROTEIN, HUMAN; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CELL SPECIFICITY; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG PURIFICATION; DRUG SENSITIZATION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR CELL; BIOSYNTHESIS; BYSTANDER EFFECT; CELL CYCLE; CELL SURVIVAL; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BYSTANDER EFFECT; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOHEXIMIDE; ETHER-A-GO-GO POTASSIUM CHANNELS; GENE EXPRESSION; HUMANS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL;

EID: 80052559599     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-109     Document Type: Article

References (51)

1. van Brussel JP, Mickisch GH. Multidrug resistance in prostate cancer. Onkologie 2003, 26:175-181. 10.1159/000071510, 12771527.
2. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005, 23:1-9. 10.1007/s00345-004-0473-1, 15770516.
3. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006, 5:147-159. 10.1038/nrd1957, 16424916.
4. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003, 10:66-75. 10.1038/sj.cdd.4401187, 12655296.
5. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003, 15:185-193. 10.1016/S1044-5323(03)00031-9, 14563117.
6. Muhlenbeck F. The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation. J Biol Chem 2000, 275:32208-32213.
7. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000, 275:23319-23325. 10.1074/jbc.M910438199, 10770955.
8. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163. 10.1038/5517, 9930862.
9. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997, 7:813-820. 10.1016/S1074-7613(00)80399-4, 9430226.
10. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001, 3:535-546. 10.1038/sj.neo.7900203, 1506567, 11774036.
11. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, Kalthoff H, Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19:5477-5486. 10.1038/sj.onc.1203936, 11114725.
12. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821. 10.1126/science.277.5327.818, 9242611.
13. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002, 8:274-281. 10.1038/nm0302-274, 11875499.
14. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Sanlioglu S. Adenovirus-mediated IKKβKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Therapy 2005, 13:21-31.
15. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195. 10.1038/40657, 9217161.
16. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304. 10.1038/40901, 9230442.
17. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004, 5:25-35. 10.1016/S1535-6108(03)00332-5, 14749124.
18. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004, 11(Suppl 1):S86-96.
19. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003, 102:303-310. 10.1182/blood-2002-09-2975, 12637321.
20. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004, 22:304-311. 10.1081/CNV-120030218, 15199612.
21. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001, 299:31-38.
22. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. International Journal of Cancer 2004, 109:281-290.
23. Bremer E, van Dam GM, de Bruyn M, van Riezen M, Dijkstra M, Kamps G, Helfrich W, Haisma H. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol Ther 2008, 16:1919-1926. 10.1038/mt.2008.203, 18813279.
24. ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009, 23:1389-1397. 10.1038/leu.2009.34, 19262596.
25. de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA, van Waarde A, Helfrich W, Bremer E. Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Molecular Cancer 2010, 9:301. 10.1186/1476-4598-9-301, 3000402, 21092273.
26. Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, Stühmer W. Role of voltage-gated potassium channels in cancer. J Membr Biol 2005, 205:115-124. 10.1007/s00232-005-0776-1, 16362499.
27. Prevarskaya N, Skryma R, Bidaux G, Flourakis M, Shuba Y. Ion channels in death and differentiation of prostate cancer cells. Cell Death Differ 2007, 14:1295-1304. 10.1038/sj.cdd.4402162, 17479110.
28. Mello de Queiroz F, Suarez-Kurtz G, Stühmer W, Pardo LA. Ether a go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer 2006, 5:42. 10.1186/1476-4598-5-42, 1618397, 17022811.
29. Hemmerlein B, Weseloh RM, de Queiroz FM, Knötgen H, Sánchez A, Rubio ME, Martin S, Schliephacke T, Jenke M, Radzun HJ, et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer 2006, 5:41. 10.1186/1476-4598-5-41, 1621079, 17022810.
30. Agarwal J, Griesinger F, Stühmer W, Pardo L. The potassium channel Ether a go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Molecular Cancer 2010, 9:18. 10.1186/1476-4598-9-18, 2835655, 20105281.
31. Downie BR, Sánchez A, Knötgen H, Contreras-Jurado C, Gymnopoulos M, Weber C, Stühmer W, Pardo LA. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J Biol Chem 2008, 283:36234-36240. 10.1074/jbc.M801830200, 2606018, 18927085.
32. Gómez-Varela D, Zwick-Wallasch E, Knötgen H, Sanchez A, Hettmann T, Ossipov D, Weseloh R, Contreras-Jurado C, Rothe M, Stühmer W, Pardo LA. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res 2007, 67:7343-7349. 10.1158/0008-5472.CAN-07-0107, 17671204.
33. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001, 61:3330-3338.
34. Shi M, Xie Z, Yu M, Shen B, Guo N. Controlled growth of Chinese hamster ovary cells and high expression of antibody-IL-2 fusion proteins by temperature manipulation. Biotechnol Lett 2005, 27:1879-1884. 10.1007/s10529-005-3897-9, 16328984.
35. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dorken B, Schulze-Osthoff K, Daniel PT. Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J 2003, 22:3580-3590. 10.1093/emboj/cdg343, 165613, 12853473.
36. Tanaka F, Kawakami A, Tamai M, Nakamura H, Iwanaga N, Izumi Y, Arima K, Aratake K, Huang M, Kamachi M, et al. IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: novel finding of cycloheximide-regulating death receptor expression. Int J Mol Med 2005, 15:833-839.
37. Brooks AD, Sayers TJ. Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 2005, 54:499-505. 10.1007/s00262-004-0595-8, 15614529.
38. Davidovich IA, Levenson AS, Levenson Chernokhvostov VV. Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance. Cancer Lett 2004, 211:189-197. 10.1016/j.canlet.2004.03.026, 15219942.
39. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007, 67:1641-1653. 10.1002/pros.20653, 17823925.
40. Miao L, Yi P, Wang Y, Wu M. Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703. Eur J Biochem 2003, 270:2721-2731. 10.1046/j.1432-1033.2003.03639.x, 12823542.
41. Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 2002, 1:520-527. 10.4161/cbt.1.5.174, 12496481.
42. García-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stühmer W, Pardo LA. Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol 2004, 124:301-317. 10.1085/jgp.200409041, 2233905, 15365094.
43. Almasan A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine & Growth Factor Reviews 2003, 14:337-348. 10.1016/S1359-6101(03)00029-7, 21898865.
44. Nesterov A, Ivashchenko Y, Kraft AS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 2002, 21:1135-1140. 10.1038/sj.onc.1205151, 11850832.
45. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001, 276:10767-10774. 10.1074/jbc.M005196200, 11278284.
46. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002, 9:164-172. 10.1038/sj.cgt.7700420, 11857034.
47. Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jegou B, Patard JJ, Guillaudeux T. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 2006, 66:987-995. 10.1002/pros.20421, 16541419.
48. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005, 5:54. 10.1186/1471-2407-5-54, 1156874, 15916713.
49. Jin Z, Dicker DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002, 1:82-89.
50. Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005, 62:165-186. 10.1002/pros.20126, 15389801.
51. Bremer E, Samplonius D, Kroesen B-J, van Genne L, de Leij L, Helfrich W. Exceptionally Potent Anti-Tumor Bystander Activity of an scFv:sTRAIL Fusion Protein with Specificity for EGP2 Toward Target Antigen-Negative Tumor Cells. Neoplasia 2004, 6:636-645. 10.1593/neo.04229, 1531668, 15548373.